Clinical Trial Update: Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of a three-drug combination (erlotinib, gemcitabine, nab-paclitaxel) in advanced pancreatic cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• Gemzar (gemcitabine) (gemcitabine)
• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Advanced Pancreatic Cancer | Phase 1 | Status: COMPLETED